Novartis: positive results for Jakavi published in NEJM

(CercleFinance.com) - Novartis has announced that the New England Journal of Medicine (NEJM) has published positive results from the REACH3 Phase III trial for Jakavi in chronic GvHD.


This study demonstrates that Jakavi (ruxolitinib) significantly improves outcomes in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (GvHD) compared to best available therapy (BAT).

Patients with chronic GvHD can have severe and life-threatening symptoms in different organs of the body, making the disease more difficult to treat and increasing the risk of poor outcomes. However, with these new results from REACH3, it is clearer to see the potential benefits of what could become a new standard of care for patients with chronic GvHD who have not responded adequately to first-line steroids.


Copyright (c) 2021 CercleFinance.com. All rights reserved.